title: Patient experience with mupirocin or povidone-iodine nasal decolonization.
abstract: Led by the federal government, the payers of health care are enacting policies designed to base provider reimbursement on the quality of care they render. This study evaluated and compared patient experiences and satisfaction with nasal decolonization with either nasal povidone-iodine (PI) or nasal mupirocin ointment (MO). A total of 1903 patients were randomized to undergo preoperative nasal decolonization with either nasal MO or PI solution. All randomized patients were also given 2% chlorhexidine gluconate topical wipes. Patients were interviewed prior to discharge to assess adverse events and patient experience with their assigned preoperative antiseptic protocol. Of the 1903 randomized patients, 1679 (88.1%) were interviewed prior to discharge. Of patients receiving PI, 3.4% reported an unpleasant or very unpleasant experience, compared with 38.8% of those using nasal MO (P<.0001). Sixty-seven percent of patients using nasal MO believed it to be somewhat or very helpful in reducing surgical site infections, compared with 71% of patients receiving PI (P>.05). Being recruited as an active participant in surgical site infection prevention was a positive experience for 87.2% of MO patients and 86.3% of PI patients (P=.652). Those assigned to receive PI solution preoperatively reported significantly fewer adverse events than the nasal MO group (P<.01). Preoperative nasal decolonization with either nasal PI or MO was considered somewhat or very helpful by more than two-thirds of patients.
authors: Jed
authors: J
authors: Maslow
authors: Lorraine
authors: L
authors: Hutzler
authors: Germaine
authors: G
authors: Cuff
authors: Andrew
authors: A
authors: Rosenberg
authors: Michael
authors: M
authors: Phillips
authors: Joseph
authors: J
authors: Bosco
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002353:Carrier State / Q000188:drug therapy; D019538:Health Care Surveys; D006801:Humans; D016712:Mupirocin / Q000008:administration & dosage* / Q000009:adverse effects; D009296:Nasal Cavity / Q000187:drug effects* / Q000382:microbiology; D017060:Patient Satisfaction; D011206:Povidone-Iodine / Q000008:administration & dosage* / Q000009:adverse effects; D012646:Self Administration; D057566:Self Report; D013530:Surgical Wound Infection / Q000382:microbiology / Q000517:prevention & control*
chemical_list: D000890:Anti-Infective Agents; D011206:Povidone-Iodine; D016712:Mupirocin